Kathryn Kloss
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 30.1% of the total. Reporting peaked in 2023 at $12,917 and has fallen 68.1% since, to $4,123 in 2025. Among medical clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $46.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$10K
- AbbVie$8K
- Idorsia Pharmaceuticals US Inc$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$765
- Neurocrine Biosciences, Inc.$737
- plus $7K from 26 others
What the payments were for
- Speaking & faculty fees$18,06955%
- Travel & lodging$3631%
- Food & beverage$14,34644%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 93 | $9,878 |
| AbbVie | 95 | $8,140 |
| Idorsia Pharmaceuticals US Inc | 30 | $4,060 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $2,205 |
| Teva Pharmaceuticals USA, Inc. | 45 | $765 |
| Neurocrine Biosciences, Inc. | 45 | $737 |
| Axsome Therapeutics, Inc. | 24 | $651 |
| Noven Therapeutics, LLC | 30 | $586 |
| Johnson & Johnson | 23 | $566 |
| Alkermes, Inc. | 26 | $556 |
| Corium, LLC | 28 | $533 |
| Lundbeck LLC | 23 | $487 |
| Almatica Pharma LLC | 23 | $451 |
| Tris Pharma Inc | 22 | $419 |
| Vanda Pharmaceuticals Inc. | 11 | $275 |
| Neos Therapeutics, LP | 16 | $274 |
| Bausch Health US, LLC | 14 | $271 |
| Avanir Pharmaceuticals, Inc. | 9 | $269 |
| Sunovion Pharmaceuticals Inc. | 20 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $242 |
| Supernus Pharmaceuticals, Inc. | 10 | $232 |
| E.r. Squibb & Sons, L.L.C. | 7 | $225 |
| Eisai Inc. | 10 | $191 |
| Jazz Pharmaceuticals Inc. | 7 | $151 |
| Harmony Biosciences LLC | 4 | $145 |
| Noven Pharmaceuticals, Inc. | 1 | $125 |
| Adlon Therapeutics L.p. | 3 | $56 |
| Merck | 2 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,842 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 15 | $335,707 |
| VraylarCariprazine Hcl | 16 | $22,476 |
| SunosiSolriamfetol Hcl | 15 | $12,639 |
| Aripiprazole | 54 | $10,026 |
| Duloxetine Hcl | 48 | $1,265 |
| Clonazepam | 113 | $1,155 |
| Alprazolam | 118 | $1,104 |
| Bupropion XlBupropion Hcl | 53 | $1,035 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $821 |
| Buspirone Hcl | 36 | $763 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $760 |
| Quetiapine Fumarate | 41 | $652 |
| Lamotrigine | 53 | $619 |
| Trazodone Hcl | 57 | $495 |
| Escitalopram Oxalate | 29 | $495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $275 | $335,70715 claims |
| AbbVieVraylar | $8,140 | $22,47616 claims |
| Axsome Therapeutics, Inc.Sunosi | $651 | $12,63915 claims |
| Almatica Pharma LLCSertraline Hcl | $451 | $17861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.
Other medical in Tampa
- Sandra SnyderTampa$156K
- Christopher RayTampa$41K
- Susan FerreyTampa$16K
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.